It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.
